Postoperative Analgesia
Conditions
Interventions
Tegileridine Group:Loading dose: Slowly intravenously inject 0.05 mg/kg of telitacicept fumarate before the end of the surgery. PCIA regimen: Telitacicept fumarate 0.05 mg/ml + tropisetron 10 mg + nor
Sufentanil Group:Loading dose: Slowly inject 10 µg sufentanil intravenously before the end of the surgery. PCIA regimen (departmental routine): sufentanil 2 µg/kg + tropisetron 10 mg + normal saline t
Sponsors
The Second Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing abdominal surgery in the general surgery department; 2. Aged 18 <=age <=65, meeting American Society of Anesthesiologists (ASA) physical status classification I–III; 3. Body Mass Index (BMI) 18.5 <= BMI <=30; 4. No significant abnormalities noted on preoperative electrocardiogram and pulmonary function tests; 5. Patients who have received informed consent and signed the surgical and general anaesthesia consent forms.
Exclusion criteria
Exclusion criteria: 1. Patients with severe chronic obstructive pulmonary disease, bronchial asthma or other respiratory conditions, difficult airways, or significant respiratory depression (oxygen saturation below 90%); 2. Patients with known or suspected gastrointestinal obstruction, including paralytic ileus; 3. Individuals with a history of substance abuse (including drug abuse, alcohol abuse, or addiction); 4. Patients with severe psychiatric disorders requiring anti-anxiety medication, sedatives, antipsychotics, or other opioid medications; 5. Patients with severe cardiac, hepatic, renal, or other organ diseases; 6. Concomitant use of known QT interval-prolonging medications (e.g., moxifloxacin, quinidine, amiodarone) or underlying conditions associated with QT prolongation (e.g., ventricular arrhythmias, untreated hypokalaemia or hypomagnesaemia); 7. Coagulation disorders; severe hypovolaemia or hypotension; 8. Concurrent immune or haematological system disorders; 9. Patients undergoing conversion to open surgery; 10. Individuals with known hypersensitivity to opioids or any component of this product.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Respiratory rate;Pulse oximetry; | — |
Countries
China
Contacts
Public ContactYuan Yingchuan
The Second Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed